Scroll Back to Top
Accessibility
Accessibility

Molecular Tumor Board: 67-year-old male with HER2-positive, PD-L1 positive advanced gastric adenocarcinoma and 70-year-old male with HER2-negative, PD-L1 negative metastatic gastric adenocarcinoma

What is the current and future state of biomarker testing in gastric cancer?

Find out in this molecular tumor board where we present two cases of advanced stage gastric cancer with contrasting molecular features. We reviewed current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. We also discussed best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology.


 

Read more »
February 12, 2024

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

This study reports a prespecified exploratory biomarker analysis of the Phase III PARAGIGM trial, which demonstrated increased overall survival with first-line anti-EGFR (panitumumab) therapy as compared with anti-vascular endothelial growth factor (bevacizumab) therapy in combination with modified FOLFOX6 in RAS wild-type metastatic colorectal ca

Read more »
Subscribe to